TY  - JOUR
AU  - Munoz-Guglielmetti, Diego
AU  - Sanchez-Lorente, David
AU  - Reyes, Roxana
AU  - Martinez, Daniel
AU  - Lucena, Carmen
AU  - Boada, Marc
AU  - Paredes, Pilar
AU  - Parera-Roig, Marta
AU  - Vollmer, Ivan
AU  - Mases, Joel
AU  - Martin-Deleon, Roberto
AU  - Castillo, Sergi
AU  - Benegas, Mariana
AU  - Munoz, Silvia
AU  - Mayoral, Maria
AU  - Cases, Carla
AU  - Molla, Meritxell
AU  - Casas, Francesc
PY  - 2021
DO  - 10.5306/wjco.v12.i11.1047
SN  - 2218-4333
UR  - https://hdl.handle.net/10668/25777
T2  - World journal of clinical oncology
AB  - BACKGROUNDNeoadjuvant treatment (NT) with chemotherapy (Ch) is a standard option for resectable stage III (N2) NSCLC. Several studies have suggested benefits with the addition of radiotherapy (RT) to NT Ch. The International Association for the Study...
LA  - en
PB  - Baishideng publishing group inc
KW  - Non-small cell lung cancer
KW  - Chemotherapy
KW  - Chemoradiotherapy
KW  - Neoadjuvant treatment
KW  - Resectable stage III
KW  - Pathological response
KW  - Cell lung-cancer
KW  - Preoperative chemotherapy
KW  - Induction chemotherapy
KW  - Phase-ii
KW  - Concurrent chemoradiotherapy
KW  - Surgical resection
KW  - Surgery
KW  - Chemoradiation
KW  - Survival
KW  - Radiotherapy
TI  - Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations
TY  - research article
VL  - 12
ER  -